RTI-31 explained

(–)-2β-Carbomethoxy-3β-(4'-chlorophenyl)tropane (RTI-4229-31) is a synthetic analog of cocaine that acts as a stimulant.[1] Semi-synthesis of this compound is dependent upon the availability of cocaine starting material. According to the article,[1] RTI-31 is 64 times the strength of cocaine in terms of its potency to elicit self-administration in monkeys. WIN 35428 was 6 times weaker than RTI-31, whereas RTI-51 was 2.6 times weaker than RTI-31.

A further advantage, in addition to potency of this compound, is that its duration of activity is longer than for cocaine. It could therefore be considered within the context as an agonist based therapy for treating cocaine addiction, although it is actually RTI-336 that entered into clinical trials with this in mind. RTI-31 is already completely psychoactive in its own right meaning that further chemical manipulation should be viewed as an option that is not strictly necessary. RTI-336 is actually made using RTI-31 as starting material. RTI-31 is not an entirely selective DRI in that it also has appreciable SERT and NET blocking affinity. RTI-31 can easily be "cleaned" though, as is done, for instance, by replacing the carbomethoxy ester with a more sterically occluded substituent such as is done for RTI-113.

Binding and uptake selectivity

Based on the uptake of tritiated biogenic monoamine radiotracers it can be confirmed by observing the figures in the attached table that RTI-31 is a relatively balanced reuptake inhibitor wrt the D/N/S ratio.

The binding ligand affinities for the different transporters is skewed somewhat in favor of the DAT; there may be some bias in the data. The reason for this could be that WIN35428 is relatively easier to displace from the DAT versus paroxetine from the SERT, because of the higher binding constant of the former compound.

Also it needs to be borne in mind the idea of transporter promiscuity.[2] It may be possible that the NE levels are raised, at least in part, through DAT blockade.

RTI-31 lies somewhere in the middle of the table between troparil on one end and RTI-55 on the other. It is not as selective as RTI-113 for the DAT, but is more selective than Dichloropane is for this transporter. RTI-31 also has some muscarinic acetylcholine agonist activity.

MAT IC50 (and Ki) for simple phenyltropanes with 1R,2S,3S stereochemistry.[3]
Compound[<sup>3</sup>H]CFT[<sup>3</sup>H]DA[<sup>3</sup>H]Nisoxetine[<sup>3</sup>H]NE[<sup>3</sup>H]Paroxetine[<sup>3</sup>H]5-HT
Cocaine[4] 89.1275 cf. 2413300 (1990)119 cf. 1611050 (45)177 cf. 112
Troparil2349.8920 (550)37.21960 (178)173
WIN 3542813.923.0835 (503)38.6692 (63)101
RTI-311.13.6837 (22)5.8644.5 (4.0)5.00
RTI-113[5] 1.985.252,9262422,340391
RTI-511.7?37.4 (23)?10.6 (0.96)?
RTI-551.31.9636 (22)7.514.21 (0.38)1.74
RTI-321.77.0260 (36)8.42240 (23)19.4
Data in Above table from rats brains (1995). More recent work has advocated using cloned human transporters.

See also

Notes and References

  1. Wee S, Carroll FI, Woolverton WL . A reduced rate of in vivo dopamine transporter binding is associated with lower relative reinforcing efficacy of stimulants . Neuropsychopharmacology . 31 . 2 . 351–62 . February 2006 . 15957006 . 10.1038/sj.npp.1300795 . 7224342 . free .
  2. Daws LC . Unfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacy . Pharmacology & Therapeutics . 121 . 1 . 89–99 . January 2009 . 19022290 . 2739988 . 10.1016/j.pharmthera.2008.10.004 .
  3. Carroll FI, Kotian P, Dehghani A, Gray JL, Kuzemko MA, Parham KA, Abraham P, Lewin AH, Boja JW, Kuhar MJ . 6 . Cocaine and 3 beta-(4'-substituted phenyl)tropane-2 beta-carboxylic acid ester and amide analogues. New high-affinity and selective compounds for the dopamine transporter . Journal of Medicinal Chemistry . 38 . 2 . 379–88 . January 1995 . 7830281 . 10.1021/jm00002a020 .
  4. Kozikowski AP, Johnson KM, Deschaux O, Bandyopadhyay BC, Araldi GL, Carmona G, Munzar P, Smith MP, Balster RL, Beardsley PM, Tella SR . 6 . Mixed cocaine agonist/antagonist properties of (+)-methyl 4beta-(4-chlorophenyl)-1-methylpiperidine-3alpha-carboxylate, a piperidine-based analog of cocaine . The Journal of Pharmacology and Experimental Therapeutics . 305 . 1 . 143–50 . April 2003 . 12649362 . 10.1124/jpet.102.046318 .
  5. Damaj MI, Slemmer JE, Carroll FI, Martin BR . Pharmacological characterization of nicotine's interaction with cocaine and cocaine analogs . The Journal of Pharmacology and Experimental Therapeutics . 289 . 3 . 1229–36 . June 1999 . 10336510 .